FDA approves Vyleesi for hypoactive sexual desire disorder in premenopausal women

FDA approves Vyleesi for hypoactive sexual desire disorder in premenopausal women

FDA approves Vyleesi (bremelanotide) for hypoactive sexual desire disorder (HSDD)

Silver Spring, MD (STL.News) – The U.S. Food and Drug Administration Friday approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

“There are women who, for no known reason, have reduced sexual desire that causes marked distress, and who can benefit from safe and effective pharmacologic treatment.  Today’s approval provides women with another treatment option for this condition,” said Hylton V.

Continue reading FDA approves Vyleesi for hypoactive sexual desire disorder in premenopausal women at STL.News.